Drug
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
Marketed as BIKTARVY.
Generic name
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
Brand names
BIKTARVY
First FDA approval
2018-02-07
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA210251 | BIKTARVY | 2018-02-07 | GILEAD SCIENCES INC |
Manufacturers
GILEAD SCIENCES INC
Frequently asked questions
When was bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate FDA approved?
Earliest FDA approval on record: 2018-02-07.
What brand names are sold as bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate?
BIKTARVY.
Sources
Appeal a bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com